Evidence map›Paper›PMID 30875891›Full record

ArticleMolecules (Basel, Switzerland)2019

EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models.

Ariadna Giró-Perafita, Marc Rabionet, Marta Planas, Lidia Feliu, Joaquim Ciurana, Santiago Ruiz-Martínez, Teresa Puig

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Role of EGFR and FASN in breast cancer progression.Journal of cell communication and signaling · 2023
    Review
  10. Article
  11. Fatty acid synthetase expression in triple-negative breast cancer.Journal of pathology and translational medicine · 2022
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ariadna Giró-PerafitaPerlmutter Cancer Center, NYU School of Medicine, 522 First Avenue, Smilow Research Building, Room 1104, New York, NY 10016, USA. ariadna.giroperafita@nyulangone.org.ORCID 0000-0002-1055-7123
Marc RabionetNew Therapeutic Targets Laboratory (TargetsLab)-Oncology Unit, Department of Medical Sciences, Faculty of Medicine, University of Girona, Emili Grahit 77, 17003 Girona, Spain. m.rabionet@udg.edu.ORCID 0000-0003-1257-9286
Marta PlanasLaboratori d'Innovació en Processos i Productes de Síntesi Orgànica (LIPPSO), Department of Chemistry, University of Girona, Maria Aurèlia Capmany 69, 17003 Girona, Spain. marta.planas@udg.edu.ORCID 0000-0003-4988-4970
Lidia FeliuLaboratori d'Innovació en Processos i Productes de Síntesi Orgànica (LIPPSO), Department of Chemistry, University of Girona, Maria Aurèlia Capmany 69, 17003 Girona, Spain. lidia.feliu@udg.edu.ORCID 0000-0001-9792-6106
Joaquim CiuranaProduct, Process and Production Engineering Research Group (GREP), Department of Mechanical Engineering and Industrial Construction, University of Girona, Maria Aurèlia Capmany 61, 17003 Girona, Spain. quim.ciurana@udg.edu.ORCID 0000-0002-6574-5551
Santiago Ruiz-MartínezNew Therapeutic Targets Laboratory (TargetsLab)-Oncology Unit, Department of Medical Sciences, Faculty of Medicine, University of Girona, Emili Grahit 77, 17003 Girona, Spain. santiago.ruiz@udg.edu.
Teresa PuigNew Therapeutic Targets Laboratory (TargetsLab)-Oncology Unit, Department of Medical Sciences, Faculty of Medicine, University of Girona, Emili Grahit 77, 17003 Girona, Spain. teresa.puig@udg.edu.
Universitat de Girona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies showed that Fatty Acid Synthase (FASN), a lipogenic enzyme overexpressed in several carcinomas, plays an important role in drug resistance. Furthermore, the enrichment of Breast Cancer Stem Cell (BCSC) features has been found in breast tumors that progressed after chemotherapy. Hence, we used the triple negative breast cancer (TNBC) cell line MDA-MB-231 (231) to evaluate the FASN and BCSC population role in resistance acquisition to chemotherapy. For this reason, parental cell line (231) and its derivatives resistant to doxorubicin (231

Indexed as

Antineoplastic AgentsCatechinCell Line, TumorCell ProliferationCell SurvivalDoxorubicinDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFatty Acid Synthase, Type IFemaleGene Expression Regulation, NeoplasticHumansMolecular StructureNeoplastic Stem CellsPaclitaxelTriple Negative Breast NeoplasmsAntineoplastic AgentsCatechinDoxorubicinepigallocatechin gallateFASN protein, humanFatty Acid Synthase, Type IPaclitaxelcancer stem cellsEGCGFASN inhibitionfatty acid metabolismG28polyphenolic compoundtriple-negative breast cancer

Identifiers

PMID30875891
PMCPMC6471537
OpenAlexW2922159962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.